Drug Information

Drug General Information
Drug ID
D0X4MN
Former ID
DNCL003418
Drug Name
CC-930
Drug Type
Small molecular drug
Indication Idiopathic pulmonary fibrosis; Discoid lupus erythematosus [ICD9: 516.3, 695.4; ICD10:J84.1, L93.0] Phase 2 [523174], [523684]
Company
Celgene
Structure
Download
2D MOL

3D MOL
Formula
C21H23F3N6O2
Canonical SMILES
C1CC(CCC1NC2=NC=C3C(=N2)N(C(=N3)NC4=C(C=C(C=C4F)F)F)C5C<br />COC5)O
InChI
1S/C21H23F3N6O2/c22-11-7-15(23)18(16(24)8-11)28-21-27-17-9-25-20(26-12-1-3-14(31)4-2-12)29-19(17)30(21)13-5-6-32-10-13/h7-9,12-14,31H,1-6,10H2,(H,27,28)(H,25,26,29)/t12?,13-,14?/m0/s1
InChIKey
IBGLGMOPHJQDJB-MOKVOYLWSA-N
PubChem Compound ID
11597537
PubChem Substance ID
16700178, 42764371, 56402244, 79994640, 134220817, 135266969, 135626886, 136925463, 136935363, 136968440, 137484740, 137484767, 170484313, 172821457, 175268478, 186014863, 210275235, 210280873, 228269363, 228269369, 230656885, 233624101, 235502621, 240527896, 242725417, 247130232, 249134492
Target and Pathway
Target(s) Jun N terminal kinase Target Info Modulator [533058]
References
Ref 523174ClinicalTrials.gov (NCT01203943) A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health.
Ref 523684ClinicalTrials.gov (NCT01466725) A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus. U.S. National Institutes of Health.
Ref 533058In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.